Search

Your search keyword '"O'Reilly, Susan E."' showing total 21 results
Start Over Author "O'Reilly, Susan E."
21 results on '"O'Reilly, Susan E."'

4. The impact of new chemotherapeutic and hormone agents on survival in a population-based cohort of women with metastatic breast cancer

Author

Chia, Stephen K., Speers, Caroline H., D'yachkova, Yulia, Kang, Anna, Malfair-Taylor, Suzanne, Barnett, Jeff, Coldman, Andy, Gelmon, Karen A., O'Reilly, Susan E., and Olivotto, Ivo A.

Subjects
British Columbia -- Research, Breast cancer -- Care and treatment, Breast cancer -- Patient outcomes, Breast cancer -- Research, Chemotherapy -- Usage, Chemotherapy -- Research, Chemotherapy -- Patient outcomes, Cancer patients -- Research, Cancer patients -- Care and treatment, Cancer -- Chemotherapy, Cancer -- Usage, Cancer -- Research, Cancer -- Patient outcomes, Health
Published
2007

5. The treatment of primary central nervous system lymphoma in 122 immunocompetent patients: a population-based study of successively treated cohorts from the British Columbia Cancer Agency

Author

Shenkier, Tamara N., Voss, Nicholas, Chhanabhai, Mukesh, Fairey, Randall, Gascoyne, Randy D., Hoskins, Paul, Klasa, Richard, Morris, James, O'Reilly, Susan E., Pickles, Tom, Sehn, Laurie, and Connors, Joseph M.

Subjects
Radiotherapy -- Patient outcomes, Nervous system cancer -- Care and treatment, Lymphomas -- Care and treatment, Chemotherapy, Combination -- Patient outcomes, Health
Published
2005

7. Non-Hodgkin's lymphoma. II: management problems

Author

O'Reilly, Susan E. and Connors, Joseph M.

Subjects
Non-Hodgkin's lymphomas -- Care and treatment, Health, Care and treatment
Abstract

In the first of our articles on non-Hodgkin's lymphoma we discussed identification, staging, and basic management.[1] In this article we discuss some of the conditions which present management problems and [...]

Published
1992

8. Non-Hodgkin's lymphoma. I: characterisation and treatment

Author

O'Reilly, Susan E. and Connors, Joseph M.

Subjects
Non-Hodgkin's lymphomas -- Care and treatment, Health, Care and treatment
Abstract

The non-Hodgkin's lymphomas are a heterogeneous collection of lymphoproliferative malignancies whose clinical behaviour, prognosis, and management vary widely according to histological subtype, stage, and bulk of disease. They are the [...]

Published
1992

9. Randomized Trial of Tamoxifen Versus Combined Tamoxifen and Octreotide LAR Therapy in the Adjuvant Treatment of Early-Stage Breast Cancer in Postmenopausal Women: NCIC CTG MA.14

Author

Pritchard, Kathleen I., primary, Shepherd, Lois E., additional, Chapman, Judith-Anne W., additional, Norris, Brian D., additional, Cantin, Jacques, additional, Goss, Paul E., additional, Dent, Susan F., additional, Walde, David, additional, Vandenberg, Ted A., additional, Findlay, Brian, additional, O'Reilly, Susan E., additional, Wilson, Carolyn F., additional, Han, Lei, additional, Piura, Ettie, additional, Whelan, Timothy J., additional, and Pollak, Michael N., additional

Published
2011
Full Text
View/download PDF

13. The Effect of Group Psychosocial Support on Survival in Metastatic Breast Cancer

Author

Goodwin, Pamela J., primary, Leszcz, Molyn, additional, Ennis, Marguerite, additional, Koopmans, Jan, additional, Vincent, Leslie, additional, Guther, Helaine, additional, Drysdale, Elaine, additional, Hundleby, Marilyn, additional, Chochinov, Harvey M., additional, Navarro, Margaret, additional, Speca, Michael, additional, Masterson, Julia, additional, Dohan, Liz, additional, Sela, Rami, additional, Warren, Barbara, additional, Paterson, Alexander, additional, Pritchard, Kathleen I., additional, Arnold, Andrew, additional, Doll, Richard, additional, O'Reilly, Susan E., additional, Quirt, Gail, additional, Hood, Nicky, additional, and Hunter, Jonathan, additional

Published
2001
Full Text
View/download PDF

15. Prognostic Significance of Bcl-2 Protein Expression and Bcl-2 Gene Rearrangement in Diffuse Aggressive Non-Hodgkin's Lymphoma

Author

Gascoyne, Randy D., primary, Adomat, Sheryle A., additional, Krajewski, Stanislaw, additional, Krajewska, Maryla, additional, Horsman, Douglas E., additional, Tolcher, Anthony W., additional, O'Reilly, Susan E., additional, Hoskins, Paul, additional, Coldman, Andrew J., additional, Reed, John C., additional, and Connors, Joseph M., additional

Published
1997
Full Text
View/download PDF

16. Treatment of Advanced Hodgkin's Disease With Chemotherapy—Comparison of MOPP/ABV Hybrid Regimen With Alternating Courses of MOPP and ABVD

Author

Connors, Joseph M., primary, Klimo, Paul, additional, Adams, Grenfell, additional, Burns, Bruce F., additional, Cooper, Ian, additional, Meyer, Ralph M., additional, O'Reilly, Susan E., additional, Pater, Joseph, additional, Quirt, Ian, additional, Sadura, Anna, additional, Shustik, Chaim, additional, Skillings, Jamey, additional, Sutcliffe, Simon, additional, Verma, Shailendra, additional, Yoshida, Sam, additional, and Zee, Benny, additional

Published
1997
Full Text
View/download PDF

21. Outcome of Treatment of First Relapse of Hodgkin’s Disease After Primary Chemotherapy: Identification of Risk Factors From the British Columbia Experience 1970 to 1988

Author

Lohri, Andreas, Barnett, Michael, Fairey, Randall N., O’Reilly, Susan E., Phillips, Gordon L., Reece, Donna, Voss, Nicholas, and Connors, Joseph M.

Abstract

The outcome of treatment for a first relapse of Hodgkin’s disease after primary chemotherapy was analyzed in 80 patients. They were divided into four groups: group 1 (n = 24) had initially been treated with three cycles of (mechlorethamine, vincristine, prednisone, and procarbazine [MOPP]) and wide-field irradiation therapy; group 2 (n = 25) had six cycles of MOPP; group 3 (n = 15) and group 4 (n = 16) both initially received MOPP/ABVD (MOPP plus doxorubicin, bleomycin, vinblastine, and dacarbazine) or MOPP/ABV hybrid, but group 3 received conventional salvage regimens whereas group 4 was treated with high-dose chemotherapy and autologous bone marrow transplantation as salvage therapy (n = 16). Freedom from second failure (FF2F) was used as the major endpoint. Actuarial FF2F for all patients was 38% after a median follow-up of 75 months for patients who were alive. Risk factor analysis was performed on the 71 patients who had been treated with curative intent. The presence or absence of any one of three risk factors had a strong negative impact on outcome: stage IV disease at primary diagnosis, B symptoms at relapse, or a time from primary treatment to relapse of less than 1 year. Actuarial FF2F at 5 years was 17% in the group of patients with one or more of these three factors present (n = 49). If none of these factors was present, FF2F was 82% (n = 22) (P <.001). Even high-dose chemotherapy and autologous bone marrow transplantation were not able to overcome the negative impact of one or more risk factors (FF2F = 19%, n = 12). The outcome of salvage treatments depends most on the presence or absence of these three risk factors and less on the type of salvage treatment. Patients with none of these risk factors present have an excellent outcome if they are treated with non–cross-resistant chemotherapy, or radiotherapy, or both. Novel approaches are needed for patients with one or more of these factors present. Reports on salvage treatments for Hodgkin’s disease in first relapse after primary chemotherapy should include data on the proportion of patients having stage IV disease at diagnosis, B symptoms at relapse, and a time from primary treatment to relapse of less than 1 year.

Published
1991
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results